Could a new vaccine tackle rising rates of Lyme disease?

According to a recent study, more than 14% of the world’s
population probably has, or has had, tick-borne Lyme disease – an
infection that can cause long and debilitating symptoms. That
number is set to rise too, as climate and environment changes
continue to increase tick populations and distribution. To help
prevent some of these cases, pharmaceutical company Pfizer and
biotech company Valneva will soon be testing a new vaccine against
Lyme disease with 6,000 volunteers across Europe and in the US.
Madeleine Finlay speaks to Dr Eoin Healy about what Lyme disease is
and how the vaccine works, and hears from a special guest about
their own experience of getting ill with the disease.. Help support
our independent journalism at theguardian.com/sciencepod